Top Industry Leaders in the Nystagmus Market
iOnctura Received FDA clearance for an investigational new drug application (IND) to study roginolisib in a Phase I clinical trial for uveal melanoma. This opens up potential for a new targeted therapy option.
Delcath Systems Received FDA approval for the HEPZATO Kit, which uses hepatic delivery of melphalan to treat metastatic ocular melanoma that has spread to the liver.
Agensys Conducted a Phase II study on pegilatinated interferon alpha-2b (PEG-IFN) for the treatment of uveal melanoma showing positive results in terms of progression-free survival. Further trials are planned.
Alnylam Pharmaceuticals Ongoing Phase 3 ENVISION2 study of givosiran for primary prevention of hepatic-associated complications in patients with non-syndromic ocular melanoma with GNAQ and GNA11 mutations.
List of Nystagmus Key Companies in the Market
- Bristol-Myers Squibb Company
- NUSAPURE
- ALLERGAN
- Aerie Pharmaceuticals Inc.
- Pfizer Inc.
- Valeant Pharmaceuticals International Inc.
- Bayer AG
- Genentech Inc.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Shire
- and Santen Pharmaceutical Co. Ltd.